Everyone’s losing their minds over Science Corp’s upcoming human brain sensor implant, but they’re asking the wrong questions. Max Hodak’s company just raised $230 million and is preparing to put hardware in someone’s skull, yet the conversation remains stuck on sci-fi fantasies instead of the mundane reality of what this technology actually does.
Let me be clear: I review AI tools for a living. I’ve seen every overhyped product launch, every breathless press release, every “this changes everything” moment that fizzles into nothing. So when a Neuralink co-founder’s new venture announces its first human implant, my BS detector goes into overdrive.
What Science Corp Actually Built
Science Corp isn’t building telepathy or letting you download kung fu into your brain. They’re working on PRIMA, a wireless retinal implant designed to restore vision. That’s it. That’s the product. They’ve submitted for CE mark approval in the European Union and expect regulatory clearance by mid-2026.
Is restoring sight to blind people important? Absolutely. Is it the brain-computer interface revolution that headlines suggest? Not even close.
The company recently appointed Murat Günel as Medical Director for Brain-Computer Interfaces, signaling they’re serious about the medical side. But here’s what nobody wants to admit: medical devices are boring. They’re slow. They’re heavily regulated. They require years of clinical trials and safety data. This isn’t a software update you push on Friday afternoon.
The $230 Million Question
Science Corp’s Series C funding round pulled in serious money. Investors are betting big on Hodak’s vision. But venture capital has a terrible track record of distinguishing between genuine breakthroughs and expensive science experiments.
I’ve watched AI companies burn through hundreds of millions building products that solve problems nobody has. The neurotechnology space is even worse because the gap between laboratory demos and real-world utility is measured in decades, not quarters.
What does $230 million buy you in brain implants? Apparently, the ability to wait for regulatory approval and maybe, possibly, help some people see again. That’s a noble goal, but it’s not the neural lace future that tech evangelists keep promising.
Why This Matters for AI Tools
Here’s my actual concern as someone who evaluates AI products: the brain-computer interface narrative is poisoning realistic expectations about what technology can deliver. Every overhyped brain implant story makes it harder to have honest conversations about the AI tools that actually exist and work today.
We have language models that can write code. We have image generators that can create art. We have agents that can automate workflows. These tools are here now, not in some hypothetical 2026 future pending regulatory approval. Yet they get a fraction of the attention because they’re not as sexy as “putting chips in brains.”
Science Corp’s PRIMA implant might help restore vision to people who desperately need it. If it works, that’s genuinely wonderful. But the company’s trajectory tells us more about the current state of neurotechnology than any press release admits: we’re still in the earliest stages of figuring this out.
The Real Timeline
Mid-2026 for European approval. Then what? FDA approval for the American market could take years longer. Then manufacturing scale-up. Then training surgeons. Then insurance coverage battles. Then actual patient access.
By the time Science Corp’s technology reaches meaningful numbers of patients, we’ll be well into the 2030s. That’s not pessimism—that’s how medical devices work.
So yes, Science Corp is preparing to implant its first brain sensor in a human. That’s a milestone worth acknowledging. But let’s stop pretending this is the moment everything changes. It’s one small step in a very long journey, funded by people who may or may not see returns before the next market correction.
I’ll keep reviewing the AI tools you can actually use today. You keep reading headlines about brain implants that might work someday. We’ll see which approach delivers more value.
🕒 Published: